Genprex reports positive preclinical data for Reqorsa in ALK+ NSCLC at AACR-NCI-EORTC conference

Genprex, Inc.

Reqorsa plus alectinib shrank tumors by 79% vs 60% with alectinib alone in mouse xenograft model.
QO mediated TUSC2 overexpression induced apoptosis in ALK+ cell lines and patient-derived organoids.
Combination treatment showed reduced tumor regrowth 2 weeks after end of dosing vs single agents.
Data support potential clinical trial of Reqorsa for ALK-EML4 positive NSCLC patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.